TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) will release its earnings data before the market opens on Monday, November 4th. Analysts expect TG Therapeutics to post earnings of $0.04 per share for the quarter.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same quarter in the prior year, the firm earned ($0.34) EPS. The company’s revenue for the quarter was up 357.0% on a year-over-year basis. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Trading Up 7.3 %

TGTX stock opened at $26.90 on Friday. TG Therapeutics has a 12-month low of $9.81 and a 12-month high of $26.99. The business’s 50-day moving average is $23.51 and its 200 day moving average is $20.01. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of 44.10 and a beta of 2.21.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research note on Wednesday, September 18th. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. B. Riley increased their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, TD Cowen started coverage on shares of TG Therapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.33.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.